CASI Pharmaceuticals' ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

[News]

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).

More... (http://www.news-medical.net/news/20140707/CASI-Pharmaceuticals-ENMD-2076-gets-FDA-Orphan-Drug-designation-for-HCC-treatment.aspx)